Quarterly ResultAug 6, 2026, 04:30 PM
Lineage Cell Therapeutics Q2 Net Income $1.48M vs $(30.46)M Loss
AI Summary
Lineage Cell Therapeutics reported a net income of $1.48 million for the second quarter of 2026, a significant improvement from a net loss of $30.46 million in the same period last year. This turnaround was primarily driven by a gain from the change in fair value of warrant liability and the absence of a prior year intangible asset impairment loss, despite a decrease in total revenues. The company's cash, cash equivalents, and marketable securities stood at $50.8 million, supporting operations for at least the next twelve months.
Key Highlights
- Net income attributable to Lineage was $1.48 million in Q2 2026, compared to a net loss of $30.46 million in Q2 2025.
- Total revenues decreased to $1.07 million in Q2 2026 from $2.77 million in Q2 2025.
- Research and development expenses increased to $4.77 million in Q2 2026 from $3.11 million in Q2 2025.
- General and administrative expenses rose to $5.22 million in Q2 2026 from $4.56 million in Q2 2025.
- A $9.44 million gain from warrant liability fair value change was recorded in Q2 2026, compared to a $12.74 million loss in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $50.8 million as of June 30, 2026.
- Total shareholders' equity increased to $59.80 million as of June 30, 2026, from $43.35 million at Dec 31, 2025.
Price Impact
More from LCTX